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INTRODUCTION 
 Medulloblastoma is the most common malignant pediatric brain tumor.  This cerebellar 
neoplasm affects an estimated 1 in 150,000 children1. Medulloblastoma arises from the aberrant 
proliferation of cerebellar granule neuron progenitors (CGNPs) located in the external granule 
cell layer (EGL) of the cerebellum2,3. Current therapy for medulloblastoma involves surgical 
resection, where possible, and aggressive radiation therapy and chemotherapy4,5. With this 
standard of treatment, long-term survival of up to 80% has been achieved for patients without 
high-risk criteria4. Despite recent advancements, medulloblastoma is still incurable in 
approximately one third of patients5, and the high toxicity of the aggressive therapy often has 
detrimental effects on survivors, most notably measurable cognitive decline4,5. Understanding the 
cellular mechanisms mediating cancer growth may lead to less toxic targeted cancer therapies for 
medulloblastoma.  
 Medulloblastoma, like many other cancers, exhibits increased aerobic glycolysis and 
lactate production in the presence of oxygen, a property commonly referred to as the Warburg 
effect3,6,7. In contrast, normal, non-proliferating cells demonstrate a relatively low rate of 
glycolysis followed by oxidative phosphorylation, allowing for a high yield of ATP6,7. Even 
though aerobic glycolysis generates less ATP, it is increased in proliferative cells because it 
allows for high catabolism and uptake of glucose that can be converted into substrates for the 
synthesis of other biomolecules7. This facilitates the production of excess biomass, which can be 
used to build a new cell3,6,7. Because the Warburg effect distinguishes cancerous cells from 
normal, differentiated cells, it offers a potential area for the development of targeted cancer 
therapies.  
 The Warburg effect in cancer is influenced by the preferential expression of the 
embryonic isoform M2 of pyruvate kinase (PkM2) over the adult isoform M1 (PkM1)3,7,8,9. 
Pyruvate kinase is the enzyme responsible for catalyzing the dephosphorylation of 
phosphoenolpyruvate (PEP) into pyruvate during the final step of glycolysis7,9. PkM1 and PkM2 
isoforms are produced through alternative splicing of mutually exclusive exons within the PkM 
gene7,9. PkM1 predominates in normal, non-proliferating cells and its expression supports high 
ATP production through oxidative phosphorylation of the pyruvate produced in glycolysis7,9. 
Unlike the constitutively active PkM1, the activity of PkM2 is tightly regulated7,8. Allosteric 
binding of fructose-1,6-bisphosphate (FBP) activates tetramerization of PkM2, causing the 
enzyme to produce pyruvate for oxidative phosphorylation7,9. However, binding of tyrosine-
phosphorylated peptides to PkM2 has been found to catalyze the release of FBP8. The release of 
FBP reverts PkM2 to its less active dimer, which promotes aerobic glycolysis and lactate 
production7,9. Cancerous cells likely preferentially express PkM2 in order to take advantage of 
this complex system of regulation. Negative regulation of PkM2 may be responsible for the 
build-up of biomass in cancerous cells, as the glycolytic intermediates upstream from the 
pyruvate kinase reaction could be redistributed to other anabolic pathways3,6,7.  
The Gershon Lab has previously shown that blocking glycolysis at its start through 
genetic deletion of Hexokinase 2 (HK2) results in a marked decrease in tumor growth and 
increased differentiation of cancerous cells within medulloblastoma2. This reduction in the 
malignancy of the tumor improved survival rates for medulloblastoma-laden mice2. The effect of 
disrupting the end of glycolysis within medulloblastoma, once glycolytic intermediates have 
been formed, remains to be elucidated and was the primary goal of this research project.  
A variety of mouse lines have been created to study the biology of medulloblastoma; two 
of such models, SmoA1 and SmoM2, were used in this study. Both lines take advantage of the 
Sonic Hedgehog (Shh) pathway1,2,3,10, one of the cellular pathways implicated in 
medulloblastoma development2,4,5. In these murine models, a mutated form of the protein 
Smoothened (Smo) is constitutively activated through a transgenic W539L point mutation11,12. 
This mutation occurs in the seventh transmembrane domain of Smo, and is thought to disrupt the 
ability of Patched to inhibit Smo activity12. The resulting constitutive activation of Smo increases 
the activity of its downstream effectors, including Gli family transcription factors4,5,12 and D-
cyclins1,10. These effectors, which normally attenuate at the end of development, are responsible 
for driving the cell cycle forward. The resulting increased cellular proliferation supports tumor 
development. 
While both the SmoA1 and SmoM2 lines model medulloblastoma development, the lines 
have some key differences. The SmoA1 model expresses a constitutively active mutant allele of 
Smo under the control of the NeuroD2 promoter1. NeuroD2 is specifically expressed in the 
CGNPs of the EGL, and expression of the SmoA1 allele under this promoter results in 
medulloblastoma1,4. Tumor onset and progression in this mouse line is relatively slow, with the 
median age of medulloblastoma development at P1801. In contrast, the SmoM2 model expresses 
a different, constitutively active mutant Smo, driven by the chicken Actin promoter, in a manner 
that requires activation by co-expression of Cre recombinase. In the mouse model used in this 
study, the expression of the Cre recombinase was controlled by the human glial fibrillary acidic 
protein (hGFAP) promoter. Under this promoter, Cre recombinase is expressed by astrocytes 
beginning at age E13.5 and has been found to yield a 100% tumorigenesis rate when combined 
with the SmoM2 allele13,14. Tumor onset and progression in this mouse line is much faster than 
that of the SmoA1 line, with medulloblastoma development occurring by P123.  
The purpose of this project was to determine the relationship between a conditional 
deletion of PkM2 and survival rates of mice within these two medulloblastoma models. In 
addition, PkM2 and PkM1 expression was compared between the two murine models used, and 
any differences in phenotype resulting from the deletion of PkM2 in each model was analyzed.  
MATERIALS AND METHODS 
Animals 
 Mice were handled in compliance with Institutional Animal Care and Use Committee 
(IUCAC) regulations. NeuroD2:SmoA1 mice were provided by Dr. James Olson (Fred 
Hutchinson Cancer Research Center, Seattle WA). Math1-Cre mice were provided by David 
Rowitch (University of California at San Francisco, San Francisco, CA). SmoM2 mice were 
obtained from Jackson Laboratories (Bar Harbor, ME).  hGFAP-Cre mice were provided by Dr. 
Evan Anton (University of North Carolina, Chapel Hill, NC). PkM2fl/fl mice were provided by 
Matthew Vander Heiden (Massachusetts Institute of Technology, Cambridge, MA). These mice 
had Lox P sites flanking either end of exon 10 of the PkM gene, such that this exon would be 
deleted in the presence of a Cre recombinase. This deletion was found to prevent the expression 
of PkM2 without interfering with PkM1 expression9.  
Each of these mouse lines were crossed to establish breeders of the necessary genotypes. 
For the analysis of the SmoA1 model, mice were bred to generate mice with SmoA1tg/+ Math-1-
Cretg/+ and intact or conditionally deleted PkM2 genotypes. For the analysis of the SmoM2 
model, only the survival of hGFAP-Cretg/+ SmoM2f/w progeny with or without a conditional 
deletion of PkM2 was considered.  
Genotyping 
 One toe from each mouse was clipped between the ages of P5-P8; a different toe was 
clipped from each mouse to allow for future identification. Each toe was placed in 80 uL of tail 
lysis buffer and incubated at 55oC overnight to allow for the digestion of the tissue and release of 
DNA. Next, the genotypes of interest were determined by amplification of the DNA 
corresponding to the gene of interest (PkM2, SmoA1, SmoM2, hGFAP-Cre, etc.) by PCR. 
Platinum Blue Mastermix was used as the DNA polymerase for the SmoA1 PCR reaction, while 
Apex Mastermix was used as the DNA polymerase in all other reactions. The PCR product was 
run by electrophoresis on a 1.3% agarose gel, containing 1.2 uL of SYBR-green for 
visualization, at 150V for 50 min. The separated bands of DNA in the gel were then visualized 
under a UV-light illuminator and imaged. The genotype of each mouse was determined from 
interpretation of this gel and recorded.  
Kaplan-Meier Survival Curve 
 The health status of the mice was monitored daily. Medulloblastomas were detected by 
observation of head shape and coordination abnormalities. The date of death was recorded for 
each mouse when it was found dead in the cage, went missing and was presumed removed by 
DLAM staff, or was sacrificed due to its poor health in compliance with IUCAC regulations. A 
brain hemisphere and tumor tissue lysate from the cerebellum were harvested from each of the 
sacrificed animals to be used for further experiments. For each mouse, the Smo genotype, PkM2 
genotype, identification number, date of death, and age of death were recorded and organized 
into a table. At the end of the study, the table was imported into IBM-SPSS 19.0 statistical 
analysis software and the data was used to generate a Kaplan-Meier survival curve and statistical 
analysis.  
Histology and Immunohistochemistry 
 For each of the animals sacrificed due to poor health, a brain hemisphere was harvested 
and fixed in 4% PFA for 24 hours. The hemispheres were then transferred to solutions of 1X 
PBS, 50% EtOH/50% PBS, and 70% EtOH for approximately 24 hours each. These samples 
were then sent to the UNC Center for Gastrointestinal Biology and Disease (CGIBD) Histology 
Core to be embedded in paraffin wax, sagittally sectioned at 5 um, and mounted onto glass 
slides. Once generated, one slide from each sample was H&E stained by UNC CGIBD. The 
remaining slides for each sample were sent to the UNC Translational Pathology Laboratory 
(TPL) to be stained for PkM1 and PkM2. The stained slides were then imaged and uploaded onto 
Aperio eSlide Manager Online Database by UNC TPL.  
Quantitative RT-PCR 
 For each of the animals sacrificed due to their health, a tumor tissue lysate was harvested 
and flash frozen on dry ice. Total RNA from these tissue samples was then isolated using the 
RNeasy Mini Kit (Qiagen). Once isolated, concentration of RNA in the stock samples was 
determined using a NanoDrop spectrophotometer. Using this concentration for each sample, 1 ug 
of mRNA was used to synthesize first strand cDNA using the Invitrogen Superscript III Reverse 
Transcriptase Kit (Life Sciences). cDNA corresponding to PkM1, PkM2, and total PkM primers 
was then amplified and quantified by an Applied Biosystems 7500Fast RT PCR system, using 
BioRad SYBER Green Super Mix. The obtained CT values were normalized, and fold change in 
PkM1, PkM2, and total PkM expression for each of the genotype variants was determined 
relative to wild-type. GAPDH expression was used as an endogenous control. 
RESULTS 
SmoA1 Survivorship 
 To determine the relationship between the survival of SmoA1 mice and the loss of PkM2, 
a survival experiment was performed resulting in a Kaplan-Meier survival curve with statistical 
analysis. A survival table was constructed from the raw data of mouse PkM2 genotype and age 
of death (Appendix I). The probability of survival for any given PkM2 genotype at a given time 
point was calculated and shown on this table. From these probabilities, a survival curve for each 
of the PkM2 genotypes was graphed (Fig. 1). The mean and median age of death for mice within 
each PkM2 genotype was determined (Fig. 2a), and statistical comparisons made (Fig. 2b). 
Whereas SmoA1 mice with a wild-type PkM2 gene survived to a median age of death of P227, 
SmoA1 mice with a conditional deletion in the PkM2 gene died much earlier, with a median age 
of death of P147. This difference in survivorship shows that the rate of death, and therefore the 
rate of tumor growth is significantly accelerated in mice with a conditional deletion of PkM2. 
This indicates that a PkM2 deletion confers a survival disadvantage in the transgenic SmoA1 
mouse model.  
 
Figure 1. Kaplan-Meier survival curve for SmoA1 mice with (KO) or without (WT) a conditional deletion of PkM2. 
The data illustrates a marked decrease in survival rates for SmoA1 mice with a conditional deletion of PkM2. 
  
  
Figure 2. a) Kaplan-Meier survival data for SmoA1tg/+ mice with (KO) or without (WT) a conditional deletion of 
PkM2 with mean and median age of death and a 95% confidence interval. b) Statistical analysis of the relationship 
between the conditional deletion of PkM2 and the age of death in SmoA1tg/+ mice. The data illustrates a statistically 
significant decrease in the survival rates of SmoA1tg/+ mice with a conditional deletion of PkM2 relative to mice 
with WT PkM2. 
 
SmoM2 Survivorship 
  An identical survival experiment was performed to determine the relationship between 
the survival of hGFAP-Cretg/+ SmoM2f/w mice and the loss of PkM2, again resulting in a Kaplan-
Meier survival curve with statistical analysis. The raw data of mouse PkM2 genotype and age of 
death was used to construct a table of survival probabilities for any given PkM2 genotype at a 
given time point for the hGFAP-Cretg/+ SmoM2f/w mouse line (Appendix II). A survival curve for 
each of the PkM2 genotypes was created using these probabilities (Fig. 3). Average age of death 
for mice within each PkM2 genotype was determined (Fig. 4a), and statistical comparisons made 
(Fig. 4b). As seen in the curve, rate of death, and therefore rate of tumor growth, is not 
statistically different between each genotype. This is supported by the lack of a statistically 
significant difference in the median age of death between the two groups analyzed (Fig. 4b). 
Thus, the data indicates that a PkM2 deletion does not confer any survival advantage or 
disadvantage in the hGFAP-Cre induced SmoM2 mouse model.  
 
Figure 3. Kaplan-Meier survival curve for hGFAP-Cretg/+ SmoM2fl/w mice with (KO) or without (WT) a conditional 
deletion of PkM2. The data does not illustrate any marked change in survival rates for hGFAP-Cretg/+ SmoM2fl/w 
mice with a conditional deletion of PkM2. 
 
 
Figure 4. a) Kaplan-Meier survival data for hGFAP-Cretg/+ SmoM2fl/w mice with (KO) or without (WT) a 
conditional deletion of PkM2 with mean and median age of death and a 95% confidence interval. b) Statistical 
analysis of the relationship between the conditional deletion of PkM2 and the age of death in hGFAP-Cretg/+ 
SmoM2fl/w mice. The data does not imply any statistically significant change in the survival rates of hGFAP-Cretg/+ 
SmoM2f/w mice with a conditional deletion of PkM2 relative to mice with WT PkM2. 
 
Histology and Immunohistochemistry 
 To test the effect of the conditional deletion on protein expression between the two 
models, tissue sections harvested from mice from each survivorship study were stained for PkM1 
and PkM2 expression (Fig. 5 & 6). In the SmoA1 model, PkM1 expression was found to be high 
in the non-proliferating, differentiated cells of the cerebrum and cerebellum, and low in the 
cancerous cells in the cerebellum (Fig. 5ab). There was not a significant change in PkM1 
expression between the mice with the conditional deletion of PkM2 (Fig. 5b), and the mice wild-
type for PkM2 (Fig. 5a). PkM2 expression was higher in the cancerous cells of the cerebellum 
relative to the differentiated cells of the cerebrum in the PkM2 wild-type mice (Fig. 5c). The 
mice with a conditional deletion for PkM2 however exhibited a marked reduction in PkM2 
expression in the whole brain (Fig. 5d). In the SmoA1 model, it is also evident that the 
conditional deletion of PkM2 results in a larger tumor size and a decreased amount of normally 
developed cerebellum in the PkM2 KO mice (Fig. 5bd) relative to the PkM2 WT mice (Fig. 5ac). 
 
Figure 5. Immunohistochemistry (IHC) stains for PkM1 and PkM2 from SmoA1 mice with a conditional deletion of 
PkM2. The slides show that the conditional deletion of PkM2 does not significantly affect PkM1 expression. 
However, PkM2 expression significantly decreases with the PkM2 conditional deletion. Increased proliferation and 
decreased differentiation are evident with the PkM2 conditional deletion. a) SmoA1 PkM2 WT mouse brain stained 
for PkM1, b) SmoA1 PkM2 KO mouse brain stained for PkM1, c) SmoA1 PkM2 WT mouse brain stained for 
PkM2, d) SmoA1 PkM2 KO mouse brain stained for PkM2 
 
The pattern of expression for PkM1 and PkM2 in the SmoM2 model was found to be the 
same as the SmoA1 model. PkM1 expression was higher in the non-proliferating cells of the 
cerebrum (Fig. 6ab) and PkM2 expression was higher in the cancerous cells in the cerebellum 
(Fig. 6c). The conditional deletion of PkM2 also did not significantly change PkM1 expression 
(Fig. 6ab) but did result in a marked reduction in PkM2 expression (Fig. 6cd). In contrast 
however, PkM2 conditional deletion did not result in an apparent increased tumor size and 
decreased normal cerebellar tissue (Fig. 6), as it did in the SmoA1 model.     
 
Figure 6. Immunohistochemistry (IHC) stains for PkM1 and PkM2 from hGFAP-Cre SmoM2 mice with a 
conditional deletion of PkM2. The slides show that the conditional deletion of PkM2 does not significantly affect 
PkM1 expression. However, PkM2 expression significantly decreases with the PkM2 conditional deletion. a) 
hGFAP-Cre SmoM2 PkM2 WT mouse brain stained for PkM1, b) hGFAP-Cre SmoM2 PkM2 KO mouse brain 
stained for PkM1, c) hGFAP-Cre SmoM2 PkM2 WT mouse brain stained for PkM2, d) hGFAP-Cre SmoM2 PkM2 
KO mouse brain stained for PkM2 
 
Quantitative RT-PCR 
In addition to immunohistochemistry (IHC) of tissues, protein expression in the SmoA1 
mouse model was analyzed through quantitative RT-PCR (qPCR) of tissue lysates harvested 
from sacrificed mice from the survivorship study. These tissue lysates were analyzed for changes 
in PkM1, PkM2, and total PkM expression with the conditional deletion of PkM2 (Fig. 7). The 
results indicate a relative pattern of increased PkM1 expression and decreased PkM2 expression 
with the conditional deletion of PkM2 in medulloblastoma. Despite this relative pattern, the 
relationship between these differences and the conditional deletion did not reach statistical 
significance, except in the case of the comparison of PkM2 expression between PkM2 Het and 
PkM2 KO tumor tissues (p = 0.017). The conditional deletion slightly decreased the overall 
expression of M-isoform pyruvate kinases (PkM1/2), but this decrease also did not reach 
statistical significance.  
 
Figure 7. Fold change for expression of PkM1, PkM2 and total M-isoform pyruvate kinases (PkM1/2) for each of 
the PkM2 genotype variants relative to wild-type (WT=1). Fold change was determined using the equation 2–ΔΔCt 
relative to PkM2 WT. GAPDH was used as an endogenous control to determine ΔCT. The data illustrates the relative 
pattern of decreased PkM2 and increased PkM1 expression with the conditional deletion of PkM2. 
 
DISCUSSION 
 Previous studies have reported that PkM2 is preferentially expressed in cancers, 
potentially due to its ability to be down-regulated to slow the conversion of PEP into pyruvate 
and build biomass3,6,7. It is hypothesized that this preferential expression of PkM2 by cancerous 
cells within a tumor gives these cells an advantage that allows them to more rapidly progress 
through the cell cycle, thus promoting tumor growth6,9. Multiple studies have implicated the role 
of PkM2 expression in tumorigenesis. High PkM2 expression is associated with worse clinical 
outcomes of patients with gastric cancers7. Additionally, the conditional deletion of PkM2 was 
found to accelerate tumor formation in Brca-driven breast cancer models9. The role of PkM2 in 
the tumor development of medulloblastoma, which had not previously been elucidated, was 
expected to follow a similar pattern.  
 According to the survivorship data found by this experiment, the conditional deletion of 
PkM2 in NeuroD2: SmoA1 mice resulted in a marked decrease in overall survival time (Fig.1). 
This data aligns with our hypothesis and with previous studies that found an acceleration of 
tumorigenesis with the conditional deletion of PkM2 in breast cancer models9. Additionally, the 
lack of a reduction in tumor growth rate in PkM2 KO tumors from the SmoA1 model indicates 
that PkM2 catalytic activity is not a requirement for tumor formation. Despite its expression not 
being necessary for tumorigenesis, the preference for PkM2 expression in tumors plays a vital 
role in the acceleration of tumor growth. Due to its ability to be down-regulated and therefore 
less active than PkM1, PkM2 expression in cancerous cells likely promotes the accumulation of 
glycolytic intermediates within the cell by converting PEP into pyruvate less efficiently than 
PkM1. These intermediates can then be redistributed to other cellular anabolic pathways, adding 
to the biomass of the cell and allowing it to grow and divide more rapidly. In addition, because 
these tumors are not starving from lack of energy, nor exhibiting any physical impairment, an 
alternative metabolic pathway that compensates for the loss of PkM2 function likely exists 
within medulloblastoma.  
 In contrast, the survivorship data from the study on the hGFAP-Cretg/+ SmoM2f/w 
medulloblastoma model did not show any significant change in survivorship due to the 
conditional deletion of PkM2 (Fig. 3). Additionally, there was no change in the rate at which 
tumor growth occurred. This might have been the result of the speed at which tumors progress in 
this murine model. The majority of the mice, regardless of their PkM2 genotype, died between 
the ages of P15 and P25. Because hGFAP-Cre is activated very early in the development of the 
mouse, these tumors begin forming at a much earlier age, and thus result in the death of the 
mouse at a much earlier age. Therefore, it is possible that PkM2 has the same effect on tumor 
growth in the SmoM2 model as it does in the SmoA1 model, but that the SmoM2 mouse dies 
from its tumor before any effect from the differential expression of PkM2 can be observed. 
Unpublished data by the Gershon Lab has shown that a SmoM2 medulloblastoma model 
promoted by Math1-Cre, rather than hGFAP-Cre, also showed no change in survival time with 
the conditional deletion of PkM2. These results indicate that a lack of survival difference based 
on PkM2 genotype for the hGFAP-Cretg/+ SmoM2f/w mice is more likely due to the speed and 
potency of tumorigenesis of the SmoM2 medulloblastoma model masking the effect of the PkM2 
deletion, than to a complete lack of an effect of PkM2 deletion on tumorigenesis in this model. 
As the effect of a PkM2 deletion on survival varied between the models, PkM1 and 
PkM2 expression was analyzed to determine if a variation in protein expression also existed 
between the models. IHC of brain sections (Fig. 5,6) showed that these protein expression 
patterns mirrored one another, with no significant differences. Both models had a pattern of 
PkM1 and PkM2 expression that illustrated the preference for PkM2 over PkM1 within the 
tumor hypothesized by the Warburg effect, as PkM1 was more highly expressed in the non-
proliferating cells of the cerebrum whereas the proliferating cells of the cerebellar tumors 
expressed higher levels of PkM2. Additionally, the conditional deletion of PkM2 in both models 
resulted in a marked decrease in PkM2 expression within the whole of the brain, illustrating the 
effectiveness of the PkM2 deletion by Cre recombinase. A similarly significant decrease in fold 
change of PkM2 expression was observed between the PkM2 KO genotype and the PkM2 Het 
genotype from qPCR analysis (Fig 7).  
While no key differences in PkM1 and PkM2 expression were observed between the two 
models, the IHC data illustrated a differential phenotype in morphology between the models. 
From this data, the deletion of PkM2 in SmoA1 model appears to results in larger tumor and a 
lower amount of differentiated cerebellar tissue compared to the PkM2 WT within this model 
(Fig 5). This indicates that the inhibition of pyruvate kinase activity could provide a mechanism 
that accelerates proliferation and decelerates, or even inhibits, differentiation of normal tissue. 
The presence of such a mechanism could explain the basis for the increased tumor malignancy 
and reduction in life expectancy seen in the survival curve for SmoA1.  
A single discrepancy existed in the protein expression patterns between the IHC and 
qPCR data. From the IHC data collected, the deletion of PkM2 does not appear have an effect on 
the normal expression of PkM1, as no significant difference in PkM1 expression can be observed 
between the PkM2 WT and KO stained sections (Fig 5ab, 6ab). Based on the stained sections, 
PkM1 also does not appear to be significantly increased in the tumor with the deletion of PkM2. 
However, the data obtained through qPCR suggests otherwise, with an observed increase in the 
fold change of PkM1 expression with the deletion of the PkM2 gene. This observed increase 
however, like many of the apparent relationships suggested by the qPCR data did not reach 
statistical significance. The large standard deviation in fold change of expression within each 
genotype variant likely resulted from the variability in the age at which samples were collected, 
as the tissue lysates from which mRNA was extracted for qPCR were collected on the date of 
death of the mouse, rather than at a uniform time point. The resulting high variability in protein 
expression within genotype variants was likely responsible for the observed high standard 
deviation and low values of statistical significance. An increased sample size could compensate 
for such variability and potentially allow the patterns of differential expression observed in the 
qPCR data to reach statistical significance in future experiments. Repeating this experiment for 
tumor tissue lysates harvested from animals from the SmoM2 survivorship study would provide 
an additional look at potential differences in protein expression between the two models.  
 Because very similar expression patterns for PkM1 and PkM2 are seen between the two 
models, the differential survival phenotype observed in the survivorship studies is not likely due 
to differences in the way in which PkM2 expression is controlled in the models. Rather, these 
differences likely result from the differential rates for tumor growth, which, as discussed earlier, 
are a function of the manner in which the constituent activation of Smo is promoted. The 
transgenic control of Smo by NeuroD2 in the SmoA1 medulloblastoma model results in a slow 
forming tumor model. Because of the extended time for tumor development, this model is very 
effective at illustrating the effect of mutations that accelerate tumor growth, such as the deletion 
of PkM2, as such a mutation would have a clearly evident phenotype. In contrast, the Cre 
recombinase control over the constitutive activation of Smo results in a fast-forming tumor 
model in SmoM2. This model is not well-suited for illustrating the effect of an accelerating 
mutation on tumor formation, because such an effect would be hard to distinguish in the already 
rapid development of the tumor. This model would be more effective than the SmoA1 model at 
illustrating the effect of decelerating mutations, as the effect of these mutations would be easier 
to identify in the already shortened lifespan of SmoM2 mice.  
In addition to this investigative power, each model has other factors that influence how 
ideal of a model it is for a given study. Although the SmoM2 model is not as effective at 
studying tumor accelerating mutations, this model offers the benefit of a high degree of control 
over tumor formation on the part of the experimenter. The host tissue and developmental time 
point in which tumor formation will occur can be controlled by the selection of a variety of 
promoters to express the Cre recombinase. Additionally, this model offers a ~100% tumor 
development rate for offspring with both mutated Smo alleles and the Cre recombinase 
expressing allele. In contrast, the SmoA1 model offers less control over tumor development on 
the part of the investigator. While the relative location and time of tumor development can be 
controlled by the selection of a promoter for the mutated Smo allele, the model requires that the 
breeder mice possess the gene for tumor development. Because the breeders are at risk for 
developing tumors, and productivity of reproduction is affected by the lifespan of the mice, the 
potential for genetic drift and selection against tumor growth is a possibility in this model. All of 
these factors must be weighed in the choice of a model to investigate the effect of a particular 
mutation.  
The elucidation of the effect of PkM2 on tumor development implicates it as a potential 
target for targeted medulloblastoma therapies. Since the deletion of PkM2 was found to 
accelerate tumor growth, an increase in pyruvate kinase activity could potentially decrease or 
prevent tumor growth and formation. Inhibition of the negative regulation of PkM2 by tyrosine-
phosphorylated peptides or enhancement of the relative expression of PkM1 in cancer cells could 
serve as potential targeted therapies for medulloblastoma. Further research is needed into the 
exact mechanism by which PkM2 affects tumor growth, and how this mechanism can be 
mediated by novel targeted therapies for medulloblastoma. 
CONCLUSION 
The conditional deletion of PkM2 was found to accelerate tumor formation and decrease 
survival rates of mice in the SmoA1 medulloblastoma model but not the SmoM2 model. This 
data suggests that PkM2 catalytic activity is not a requirement for the formation of 
medulloblastoma and supports the theory that PkM2 preference in tumors is the result of its 
ability to be regulated in its glycolytic function and not due to any oncogenic transcriptional 
properties. Additionally, the lack of significant differential expression of PkM1 and PkM2 
between the models indicates that the observed differences in phenotype derive from the nature 
of the models themselves. 
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APPENDICES  
I) SmoA1 Survivorship Probability Table 
Survival Table 
Genotype Time 
(days) 
Cumulative Proportion 
Surviving at the Time 
N of 
Cumulative 
Events 
N of 
Remaining 
Cases 
Estimate Std. Error 
SmoA1 PkM2 
WT 
1 74.000 .970 .030 1 32 
2 102.000 .939 .042 2 31 
3 118.000 .909 .050 3 30 
4 133.000 .879 .057 4 29 
5 138.000 .848 .062 5 28 
6 142.000 .818 .067 6 27 
7 146.000 .788 .071 7 26 
8 162.000 .758 .075 8 25 
9 173.000 .727 .078 9 24 
10 187.000 .697 .080 10 23 
11 189.000 .667 .082 11 22 
12 193.000 .636 .084 12 21 
13 195.000 .606 .085 13 20 
14 197.000 .576 .086 14 19 
15 203.000 .545 .087 15 18 
16 214.000 .515 .087 16 17 
17 227.000 .485 .087 17 16 
18 230.000 .455 .087 18 15 
19 248.000 .424 .086 19 14 
20 263.000 .394 .085 20 13 
21 273.000 .364 .084 21 12 
22 278.000 .333 .082 22 11 
23 300.000 .303 .080 23 10 
24 302.000 . . 24 9 
25 302.000 . . 25 8 
26 302.000 . . 26 7 
27 302.000 . . 27 6 
28 302.000 . . 28 5 
29 302.000 . . 29 4 
30 302.000 . . 30 3 
31 302.000 .061 .042 31 2 
32 307.000 .030 .030 32 1 
33 335.000 .000 .000 33 0 
SmoA1 PkM2 
KO 
1 86.000 .909 .087 1 10 
2 105.000 .818 .116 2 9 
3 114.000 .727 .134 3 8 
4 128.000 .636 .145 4 7 
5 141.000 .545 .150 5 6 
6 147.000 .455 .150 6 5 
7 151.000 .364 .145 7 4 
8 155.000 .273 .134 8 3 
9 179.000 .182 .116 9 2 
10 192.000 .091 .087 10 1 
11 200.000 .000 .000 11 0 
 
II) SmoM2 Survivorship Probability Table 
Survival Table 
Genotype Time 
(days) 
Cumulative Proportion 
Surviving at the Time 
N of Cumulative 
Events 
N of Remaining 
Cases 
Estimate Std. Error 
hGFAP-Cre 
SmoM2 
PkM2 WT 
1 13.000 .857 .132 1 6 
2 14.000 .714 .171 2 5 
3 18.000 .571 .187 3 4 
4 22.000 . . 4 3 
5 22.000 .286 .171 5 2 
6 25.000 .143 .132 6 1 
7 36.000 .000 .000 7 0 
hGFAP-Cre 
SmoM2 
PkM2 KO 
1 13.000 .960 .039 1 24 
2 14.000 . . 2 23 
3 14.000 .880 .065 3 22 
4 15.000 . . 4 21 
5 15.000 .800 .080 5 20 
6 16.000 . . 6 19 
7 16.000 .720 .090 7 18 
8 17.000 . . 8 17 
9 17.000 . . 9 16 
10 17.000 . . 10 15 
11 17.000 . . 11 14 
12 17.000 . . 12 13 
13 17.000 .480 .100 13 12 
14 18.000 . . 14 11 
15 18.000 . . 15 10 
16 18.000 . . 16 9 
17 18.000 .320 .093 17 8 
18 19.000 .280 .090 18 7 
19 20.000 .240 .085 19 6 
20 21.000 . . 20 5 
21 21.000 . . 21 4 
22 21.000 .120 .065 22 3 
23 23.000 .080 .054 23 2 
24 28.000 .040 .039 24 1 
25 46.000 .000 .000 25 0 
 
